一线分子靶向治疗晚期脊索瘤的疗效与预后因素:法国肉瘤组(GSF/GETO)与法国神经肿瘤学家协会(ANOCEF)的回顾性研究
该回顾性研究纳入2004年1月至2015年12月法国15个肉瘤或神经肿瘤中心的80例晚期脊索瘤患者,评估一线分子靶向治疗(MTT)的疗效与预后因素。中位无进展生存期(PFS)为9.4个月(95%CI 6.8-16.1),中位总生存期(OS)为4.4年(95%CI 3.8-5.6);颅底原发及诊断至MTT间隔<52个月为PFS独立不良预后因素,肝转移、需阿片类镇痛、颅底原发及既往光子放疗为OS独立不良预后因素。
要点
- 一线MTT以伊马替尼为主(62例,77.5%),部分缓解5例(6.3%),疾病稳定58例(72.5%)。
- 中位PFS 9.4个月(95%CI 6.8-16.1),中位OS 4.4年(95%CI 3.8-5.6)。
- 颅底原发(PFS HR=2.5,OS HR=19.7)及诊断至MTT间隔<52个月(PFS HR=2.8)为不良预后因素。
核心结论
- 所识别的预后因素需在独立数据库中验证,但对指导治疗决策和设计进一步临床试验可能非常有用。
研究设计与样本
- 回顾性研究,纳入2004年1月至2015年12月法国15个主要肉瘤或神经肿瘤中心收治的80例晚期脊索瘤患者,评估一线分子靶向治疗的作用。
主要发现
- 男女比为46/34,中位年龄59岁(范围6-86岁),原发部位为骶骨50例(62.5%)、活动脊柱12例(15.0%)、颅底18例(22.5%),28例(36.0%)存在转移。
- 一线MTT为伊马替尼62例(77.5%)、索拉非尼11例(13.7%)、厄洛替尼5例(6.3%)、舒尼替尼1例(1.2%)、替西罗莫司1例(1.2%)。
- 疗效为部分缓解5例(6.3%)、疾病稳定58例(72.5%)、疾病进展10例(12.5%);66例可评估患者中28例(42.4%)症状改善,症状改善与客观缓解发生(p=0.005)、使用伊马替尼(p=0.020)或厄洛替尼(p=0.028)相关。
- 中位PFS为9.4个月(95%CI 6.8-16.1);PFS独立不良预后因素为颅底原发(HR=2.5,p=0.019)和诊断至MTT间隔<52个月(HR=2.8,p<0.001)。
- 中位OS为4.4年(95%CI 3.8-5.6);OS独立不良预后因素为肝转移(HR=13.2,p<0.001)、需阿片类镇痛(HR=2.9,p=0.012)、颅底原发(HR=19.7,p<0.001)和既往放疗(仅光子)(HR=2.5,p=0.024);PFS和OS在不同MTT之间无显著差异。
局限性
- 预后因素需在独立数据库中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the role of first-line Molecular Targeted Therapies (MTTs) in Advanced chordoma (AC) patients. METHODS: Retrospective study of 80 patients treated between January 2004 and December 2015 at 15 major French Sarcoma or Neurooncology Centres. RESULTS: The sex ratio M/F was 46/34. The median age was 59 (6-86) years. The primary sites were the sacrum (50, 62.5%), mobile spine (12, 15.0%), and skull base (18, 22.5%). Metastases were present in 28 patients (36.0%). The first line of MTTs consisted of imatinib (62, 77.5%), sorafenib (11, 13.7%), erlotinib (5, 6.3%), sunitinib (1, 1.2%) and temsirolimus (1, 1.2%). The reported responses were: partial response (5, 6.3%), stable disease (58, 72.5%), or progressive disease (10, 12.5%). Symptomatic improvement was seen in 28/66 assessable patients (42.4%) and was associated with an objective response occurrence (p = 0.005), imatinib (p = 0.020) or erlotinib use (p = 0.028). The median progression-free survival (PFS) was 9.4°months (95% CI, [6.8-16.1]). Two independent factors of poor prognosis for PFS were identified: a skull-based primary location (HR = 2.5, p = 0.019), and the interval between diagnosis and MTT of <52months (HR = 2.8, p < 0.001). The median overall survival (OS) was 4.4°years (95% CI, [3.8-5.6]). Four independent factors of poor prognosis for OS were identified: the presence of liver metastases (HR = 13.2, p < 0.001), pain requiring opioids (HR = 2.9, p = 0.012), skull-based primary location (HR = 19.7, p < 0.001), and prior radiotherapy (photon alone) (HR = 2.5, p = 0.024). The PFS and OS did not significantly differ between the MTT. CONCLUSIONS: The prognostic factors identified require validation in an independent database but are potently useful to guide treatment decisions and design further clinical trials.
引用
- Lebellec L, Chauffert B, Blay JY, et al. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). Eur J Cancer. 2017. PMID: 28478340. doi:10.1016/j.ejca.2017.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。